Pluristem Therapeutics

Pluristem Therapeutics is a regenerative medicine company developing a platform of novel biological products. PLX, a placenta-based cell therapy, consists of off-the-shelf products that require no tissue matching prior to administration. Each patented PLX product releases a distinct combination of therapeutic proteins in response to signals from the patient's body from tissues that have been damaged by conditions such as inflammation, ischemia, muscle injuries, hematological disorders, and exposure to radiation in order to stimulate the body's own regenerative mechanisms.
The company's technology can be used to grow PLX cells in mass quantities with batch-to-batch consistency at Pluristem's FDA-, EMA-, and PMDA-approved manufacturing facility.
Combating Coronavirus Pandemic:
The company's PLX cell therapy may potentially be used to treat COVID-19 patients with pneumonia and pneumonitis under the compassionate use program, a treatment option that allows for the use of unauthorized medicine for severely ill patients.